Holen Sie sich die Stockscreener-App
2.72
4.21%
0.11
Vorhandelsmarkt:
3.28
0.56
+20.59%
Schlusskurs vom Vortag:
$2.61
Offen:
$2.648
24-Stunden-Volumen:
434.90K
Relative Volume:
0.24
Marktkapitalisierung:
$101.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.45%
1M Leistung:
-32.84%
6M Leistung:
-42.86%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.55
$2.74
1-Wochen-Bereich:
$2.55
$2.97
52-Wochen-Spanne:
$1.61
$12.74
Metagenomi Inc Stock (MGX) Company Profile
Firmenname
Metagenomi Inc
Sektor
Branche
Telefon
(510) 871-4880
Adresse
5959 HORTON STREET, EMERYVILLE
Vergleichen Sie MGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
2.72 | 101.79M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-03-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-03-05 | Eingeleitet | TD Cowen | Outperform |
| 2024-03-05 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Metagenomi Inc Aktie (MGX) Neueste Nachrichten
Metagenomi aiming for clinical trials of gene-editing therapy in 2026 - Hemophilia News Today
Metagenomi outlines anticipated 2025 milestones - MSN
Metagenomi advances gene editing therapies into 2025 - Investing.com
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones - GlobeNewswire
Metagenomi Reports 16-Month Breakthrough in Hemophilia A Treatment Development Program - StockTitan
Metagenomi Announces New Appointment to its Board of Directors - GlobeNewswire
Metagenomi, Inc. Announces Appointment of Eric Bjerkholt to Its Board of Directors, Serving on Audit and Compensation Committees, Effective January 27, 2025 - Marketscreener.com
Metagenomi, Inc.'s (NASDAQ:MGX) market cap dropped US$12m last week; individual investors who hold 33% were hit as were institutions - Yahoo Finance
We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully - Simply Wall St
Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX) - MSN
Geode Capital Management LLC Has $734,000 Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Metagenomi CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Metagenomi: Q3 Earnings Snapshot - Marketscreener.com
Metagenomi, Inc. (NASDAQ:MGX) Short Interest Up 445.1% in December - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Shares Purchased by BNP Paribas Financial Markets - Defense World
Verition Fund Management LLC Makes New Investment in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - The Eastern Progress Online
MGX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In MGX To Contact Him Directly To Discuss Their Options - The Eastern Progress Online
2 ‘Monster’ Stocks to Snap Up Before 2025 - MSN
Metagenomi (NASDAQ:MGX) Price Target Raised to $14.00 - Defense World
MGX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Eastern Progress Online
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference 'RNA at the Bench and Bedside IV” - The Manila Times
Metagenomi Presents Highly Specific and Efficient Genome - GlobeNewswire
Metagenomi, Inc. Presents Highly Specific and Efficient Genome Editing Tools At Nature Conference RNA At the Bench and Bedside IV - Marketscreener.com
Metagenomi, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your RightsMGX - The Eastern Progress Online
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts - Benzinga
Metagenomi (NASDAQ:MGX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Metagenomi presents updated preclinical NHP data at ASH meeting - TipRanks
Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry - Simply Wall St
Metagenomi presents updated preclinical data in Hemophilia A at ASH - TipRanks
Metagenomi's Gene Therapy Shows Breakthrough 16-Month Durability in Hemophilia A Preclinical Data - StockTitan
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting - Yahoo Finance
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th - EIN News
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit - The Eastern Progress Online
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Eastern Progress Online
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
Lawsuit Deadline Notice: Metagenomi, Inc. Investors who lost over $100,000 with NASDAQ: MGX shares should contact the Shareholders Foundation - The Eastern Progress Online
Finanzdaten der Metagenomi Inc-Aktie (MGX)
Es liegen keine Finanzdaten für Metagenomi Inc (MGX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):